Are we sleeping on the job? Insomnia among men with prostate cancer

Frances Josephine Drummond


Prostate cancer is one of the most commonly diagnosed cancers in men and almost half of male cancer survivors in the US have had a prostate cancer diagnosis. Insomnia is common among cancer patients and survivors. There is evidence that cognitive behavioural therapy can be used to effectively manage insomnia among women with breast cancer. The aim of this review was to investigate the prevalence, risk factors and management of insomnia among men with prostate cancer. The effect of insomnia on the psychological health and health-related quality of life of these patients and/or survivors is also discussed. Increased awareness and knowledge of this symptom among men with prostate cancer may facilitate improved diagnosis, and management of insomnia in this large population. This in turn may improve the health-related quality of life of these men. Therefore, research into the effective management of insomnia among men with prostate cancer is essential.


prostate cancer; insomnia; androgen deprivation therapy; radiotherapy; health-related quality of life; depression; anxiety

Full Text:



Bray F, Jemal A, Grey N, Ferlay J, Forman D. Global cancer transitions according to the human development index (2008–2030): A population-based study. Lancet Oncol 2012; 13(8): 790–801. doi: 10.1016/S1470-2045(12)70211-5.

Siegel R, DeSantis C, Virgo K, Stein K, Mariotto A, Smith T, Cooper D, Gansler T, Lerro C, Fedewa S, Lin C, Leach C, Cannady RS, Cho H, Scoppa S, Hachey M, Kirch R, Jemal A, Ward E. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 2012; 62(4): 220–241. doi: 10.3322/caac. 21149.

Potosky AL, Davis WW, Hoffman RM, Standford JL, Stephenson RA, Penson DF, Harlan LC. Five-year outcomes after prostatectomy or radiotherapy for prostate cancer: The prostate cancer outcomes study. J Natl Cancer Inst 2004; 96(18): 1358–1367. doi: 10.1093/jnci/djh259.

Drummond FJ, Carsin AE, Sharp L, Comber H. Trends in prostate specific antigen testing in Ireland: Lessons from a country without guidelines. Ir J Med Sci 2010; 179(1): 43–49. doi: 10.1007/s11845-009-0376-7.

Carsin AE, Drummond FJ, Black A, van Leeuwen PJ, Sharp L, Murray LJ, Connolly D, Egevad L, Boniol M, Autier P, Comber H, Gavin A. Impact of PSA testing and prostatic biopsy on cancer incidence and mortality: Comparative study between the Republic of Ireland and Northern Ireland. Cancer Causes Control 2010; 21(9): 1523–1531. doi: 10.1007/s10552-010-9581-y.

Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer 2010; 46(4): 765–781. doi: 10.1016/j.ejca.2009.12.014.

Pashayan N, Duffy SW, Pharoah P, Greenberg D, Donovan J, Martin RM, Hamdy F, Neal DE. Mean sojourn time, overdiagnosis, and reduction in advanced stage prostate cancer due to screening with PSA: Implications of sojourn time on screening. Br J Cancer 2009; 100(7): 1198–1204. doi: 10.1038/sj.bjc.6604973.

Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Nordling S, Häggman M, Andersson SO, Bratell S, Spångberg A, Palmgren J, Steineck G, Adami HO, Johansson JE, The Scandinavian Prostate Cancer Group Study Number 4 (SPCG-4) investigators. Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 2011; 364(18): 1708–1717. doi: 10.1056/NEJMoa1011967.

Wilt TJ, Brawer MK, Jones KM, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, Nsouli I, Iyer P, Cartagena R, Snider G, Roehrborn C, Sharifi R, Blank W, Pandya P, Andriole GL, Culkin D, Wheeler T, Prostate Cancer Intervention versus Observation Trial (PIVOT) Study Group. Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med 2012; 367(3): 203–213. doi: 10.1056/NEJMoa1113162.

Korfage IJ, Essink-Bot ML, Borsboom GJ, Madalinska JB, Kirkels WJ, Habbema JD, Schröder FH, de Koning HJ. Five-year follow-up of health related quality of life after primary treatment of localized prostate cancer. Int J Cancer 2005; 116(2): 291–296. doi: 10.1002/ijc.21043.

Gavin AT, Drummond FJ, Donnelly C, O'Leary E, Sharp L, Kinnear HR. Patient-reported ‘ever had’ and ‘current’ long-term physical symptoms after prostate cancer treatments. BJU Int 2015; 116(3): 397–406. doi: 10.1111/bju.13036.

Braun DP, Gupta D, Staren ED. Predicting survival in prostate cancer: The role of quality of life assessment. Support Care Cancer 2012; 20(6): 1267–1274. doi: 10.1007/s00520-011-1213-x.

Collette L, van Andel G, Bottomley A, Oosterhof GO, Albrecht W, de Reijke TM, Fossà SD. Is baseline quality of life useful for predicting survival with hormone-refractory prostate cancer? A pooled analysis of three studies of the European organisation for research and treatment of cancer genitourinary group. J Clin Oncol 2004; 22(19): 3877– 3885. doi: 10.1200/JCO.2004.07.089.

Drummond FJ, Kinnear H, O’Leary E, Donnelly AG, Sharp L. Long-term health-related quality of life of prostate cancer survivors varies by primary treatment. Results from the PiCTure (prostate cancer treatment, your experience) study. J Cancer Surviv 2015; 9(2): 361–372. doi: 10.1007/s11764-014-0419-6.

Jønler M, Nielsen OS, Groenvold M, Hedlund PO, Damber L, Hedelin H, Waldén M, Scandinavian Prostate Cancer Group Study 5 Study Group. Quality of life in patients with skeletal metastases of prostate cancer and status prior to start of endocrine therapy: Results from the Scandinavian prostate cancer group study 5. Scand J Urol Nephrol 2005; 39(1): 42–48. doi: 10.1080/00365590410002528.

Joshi N, de Blok W, van Muilekom E, van der Poel H. Impact of posterior musculofascial reconstruction on early continence after robot-assisted laparoscopic radical prostatectomy: Results of a prospective parallel group trial. Eur Urol 2010; 58(1): 84–89. doi: 10.1016/j.eururo. 2010.03.028.

Kornblith AB, Herr HW, Ofman US, Scher HI, Holland JC. Quality of life of patients with prostate cancer and their spouses. The value of a data base in clinical care. Cancer 1994; 73(11): 2791–2802. doi:10.1002/1097-0142 (19940601)73:11<2791::AID-CNCR282073

Lilleby W, Fosså SD, Wæhre HR, Olsen DR. Long-term morbidity and quality of life in patients with localized prostate cancer undergoing definitive radiotherapy or radical prostatectomy. Int J Radiat Oncol Biol Phys 1999; 43(4): 735–743. doi: 10.1016/S0360-3016(98)00475-1.

Vordermark D, Wulf J, Markert K, Baier K, Kölbl O, Beckmann G, Bratengeier K, Noe M, Schön G, Flentje M. 3-D conformal treatment of prostate cancer to 74 Gy vs. high-dose-rate brachytherapy boost: A cross-sectional quality-of-life survey. Acta Oncol 2006; 45(6): 708–716. doi: 10.1080/02841860600710913.

Sharp L, O’Leary E, Kinnear H, Gavin A, Drummond FJ. Cancer-related symptoms predict psychological wellbeing among prostate cancer survivors: Results from the PiC-Ture study. Psychooncology 2015; 25(3): 282–291. doi: 10.1002/pon.3909.

Davidson JR, MacLean AW, Brundage MD, Schulze K. Sleep disturbance in cancer patients. Soc Sci Med 2002; 54(9): 1309–1321. doi: 10.1016/S0277-9536(01)00043-0.

Kozachik SL, Bandeen-Roche K. Predictors of patterns of pain, fatigue, and insomnia during the first year after a cancer diagnosis in the elderly. Cancer Nurs 2008; 31(5): 334–344. doi: 10.1097/01.NCC.0000305769.27227.67.

Lam K, Chow E, Zhang L, Wong E, Bedard G, Fairchild A, Vassiliou V, Alm El-Din M, Jesus-Garcia R, Kumar A, Forges F, Tseng LM, Hou MF, Chie WC, Bottomley A. Determinants of quality of life in advanced cancer patients with bone metastases undergoing palliative radiation treatment. Support Care Cancer 2013; 21(11): 3021–3030. doi: 10.1007/s00520-013-1876-6.

Savard J, Villa J, Ivers H, Simard S, Morin CM. Prevalence, natural course, and risk factors of insomnia comorbid with cancer over a 2-month period. J Clin Oncol 2009; 27(31): 5233–5239. doi: 10.1200/JCO.2008.21.6333.

Savard J, Ivers H, Villa J, Caplette-Gingras A, Morin CM. Natural course of insomnia comorbid with cancer: an 18-month longitudinal study. J Clin Oncol 2011; 29(26): 3580–3586. doi: 10.1200/JCO.2010.33.2247.

Zucca AC, Boyes AW, Linden W, Girgis A. All’s well that ends well? Quality of life and physical symptom clusters in long-term cancer survivors across cancer types. J Pain Symptom Manage 2012; 43(4): 720–731. doi: 10.1016/j. jpainsymman.2011.04.023.

Miaskowski C, Lee K, Dunn L, Dodd M, Aouizerat BE, West C, Paul SM, Cooper B, Wara W, Swift P. Sleep-wake circadian activity rhythm parameters and fatigue in oncology patients before the initiation of radiation therapy. Cancer Nurs 2011; 34(4): 255–268. doi: 10.1097/NCC.0b013e3181f65d9b.

Mercadante S, Aielli F, Adile C, Ferrera P, Valle A, Cartoni C, Pizzuto M, Caruselli A, Parsi R, Cortegiani A, Masedu F, Valenti M, Ficorella C, Porzio G. Sleep disturbances in patients with advanced cancer in different palliative care settings. J Pain Symptom Manage 2015; 50(6): 786–792. doi: 10.1016/j.jpainsymman.2015. 06.018.

Savard J, Morin CM. Insomnia in the context of cancer: A review of a neglected problem. J Clin Oncol 2001; 19(3): 895–908.

American Academy of Sleep Medicine. The international classification of sleep disorder, revised: Diagnostic and coding manual. 2nd ed. Illinois: American Academy of Sleep Medicine; 2005.

Sateia MJ, Nowell PD. Insomnia. Lancet 2004; 364(9449): 1959–1973. doi: 10.1016/S0140-6736(04)17480-1.

Kyle SD, Morgan K, Espie CA. Insomnia and health-related quality of life. Sleep Med Rev 2010; 14(1): 69–82. doi: 10.1016/j.smrv.2009.07.004.

Bastien CH, Vallières A, Morin CM. Validation of the insomnia severity index as an outcome measure for in-somnia research. Sleep Med 2001; 2(4): 297–307. doi: 10.1016/S1389-9457(00)00065-4.

Buysse DJ, Reynolds CF 3rd, Monk TH, Berman SR, Kupfer DJ. The Pittsburgh sleep quality index: A new instrument for psychiatric practice and research. Psychiatry Res 1989; 28(2): 193–213. doi: 10.1016/0165-1781(89) 90047-4.

Lee KA. Self-reported sleep disturbances in employed women. Sleep 1992; 15(6): 493–498.

Soldatos CR, Dikeos DG, Paparrigopoulos TJ. Athens insomnia scale: Validation of an instrument based on ICD-10 criteria. J Psychosom Res 2000; 48(6): 555–560. doi: 10.1016/S0022-3999(00)00095-7.

Hays RD, Martin SA, Sesti AM, Spritzer KL. Psychometric properties of the medical outcomes study sleep measure. Sleep Med 2005; 6(1): 41–44. doi: 10.1016/ j.sleep.2004.07.006.

Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JCJM, Kaasa S, Klee M, Osoba D, Razavi D, Rofe PB, Schraub S, Sneeuw K, Sullivan M, Takeda F. The European organization for research and treatment of cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85(5): 365–376. doi: 10.1093/jnci/85.5.365.

Morin CM. Insomnia: Psychological assessment and management. New York: The Guilford Press; 1993. p. 238.

Murtagh DRR, Greenwood KM. Identifying effective psychological treatments for insomnia: A meta-analysis. J Consult Clin Psychol 1995; 63(1): 79–89. doi: 10.1037/ 0022-006X.63.1.79.

Lichstein KL, Stone KC, Donaldson J, Nau SD, Soeffing JP, Murray D, Lester KW, Aguillard RN. Actigraphy validation with insomnia. Sleep 2006; 29(2): 232–239.

Savard J, Simard S, Hervouet S, Ivers H, Lacombe L, Fradet Y. Insomnia in men treated with radical prostatectomy for prostate cancer. Psychooncology 2005; 14(2): 147–156. doi: 10.1002/pon.830.

Hervouet S, Savard J, Simard S, Ivers H, Laverdière J, Vigneault E, Fradet Y, Lacombe L. Psychological functioning associated with prostate cancer: Cross-sectional comparison of patients treated with radiotherapy, brachytherapy, or surgery. J Pain Symptom Manage 2005; 30(5): 474–484. doi: 10.1016/j. jpainsymman.2005.05.011.

Dirksen SR, Epstein DR, Hoyt MA. Insomnia, depression, and distress among outpatients with prostate cancer. Appl Nurs Res 2009; 22(3): 154–158. doi: 10.1016/j.apnr. 2007.09.001.

Hanisch LJ, Gooneratne NS, Soin K, Gehrman PR, Vaughn DJ, Coyne JC. Sleep and daily functioning during androgen deprivation therapy for prostate cancer. Eur J Cancer Care 2011; 20(4): 549–554. doi: 10.1111/j.1365- 2354.2010.01226.x.

Choo R, Pearce A, Danjoux C, Morton G, Deboer G, Szumacher E, Loblaw A, Cheung P. Prospective evaluation of quality of life in prostate cancer patients receiving combined treatment of postoperative radiotherapy plus androgen suppression for PT3 or positive resection margin after radical prostatectomy. Eur Urol 2007; 52(6): 1645–1650. doi: 10.1016/j.eururo.2006.11.018.

Savard J, Hervouet S, Ivers H. Prostate cancer treatments and their side effects are associated with increased insomnia. Psychooncology 2013; 22(6): 1381–1388. doi: 10.1002/pon.3150.

Savard J, Ivers H, Savard MH, Morin CM. Cancer treatments and their side effects are associated with aggravation of insomnia: Results of a longitudinal study. Cancer 2015; 121(10): 1703–1711. doi: 10.1002/cncr.29244.

Miaskowski C, Paul SM, Cooper BA, Lee K, Dodd M, West C, Aouizerat BE, Dunn L, Swift PS, Wara W. Predictors of the trajectories of self-reported sleep disturbance in men with prostate cancer during and following radiation therapy. Sleep 2011; 34(2): 171–179.

Thomas KS, Bower J, Hoyt MA, Sepah S. Disrupted sleep in breast and prostate cancer patients undergoing radiation therapy: The role of coping processes. Psychooncology 2010; 19(7): 767–776. doi: 10.1002/pon.1639.

Induru RR, Walsh D. Cancer-related insomnia. Am J Hosp Palliat Me 2014; 31(7): 777–785. doi: 10.1177/1049909113508302.

Gapstur SM, Diver WR, Stevens VL, Carter BD, Teras LR, Jacobs EJ. Work schedule, sleep duration, insomnia, and risk of fatal prostate cancer. Am J Prev Med 2014; 46(3 Suppl 1): S26–S33. doi: 10.1016/j.amepre.2013.10.033.

Espie CA, Fleming L, Cassidy J, Samuel L, Taylor LM, White CA, Douglas NJ, Engleman HM, Kelly HL, Paul J. Randomized controlled clinical effectiveness trial of cognitive behavior therapy compared with treatment as usual for persistent insomnia in patients with cancer. J Clin Oncol 2008; 26(28): 4651–4658. doi: 10.1200/JCO. 2007.13.9006.

Casault L, Savard J, Ivers H, Savard MH, Simard S. Utilization of hypnotic medication in the context of cancer: Predictors and frequency of use. Support Care Cancer 2012; 20(6): 1203–1210. doi: 10.1007/s00520-011-1199-4.

Berger AM, Kuhn BR, Farr LA, Lynch JC, Agrawal S, Chamberlain J, Von Essen SG. Behavioral therapy intervention trial to improve sleep quality and cancer-related fatigue. Psychooncology 2009; 18(6): 634–646. doi: 10.1002/pon.1438.

Savard J, Simard S, Ivers H, Morin CM. Randomized study on the efficacy of cognitive-behavioral therapy for insomnia secondary to breast cancer, part I: Sleep and psychological effects. J Clin Oncol 2005; 23(25): 6083–6096. doi: 10.1200/JCO.2005.09.548.

Heckler CE, Garland SN, Peoples AR, Perlis ML, Shayne M, Morrow GR, Kamen C, Hoefler J, Roscoe JA. Cognitive behavioral therapy for insomnia, but not armodafinil, improves fatigue in cancer survivors with insomnia: A randomized placebo-controlled trial. Support Care Cancer 2015. doi: 10.1007/s00520-015-2996-y.

Johnson JA, Rash JA, Campbell TS, Savard J, Gehrman PR, Perlis M, Carlson LE, Garland SN. A systematic review and meta-analysis of randomized controlled trials of cognitive behavior therapy for insomnia (CBT-I) in cancer survivors. Sleep Med Rev 2015; 27: 20–28. doi: 10.1016/j.smrv.2015.07.001.

Garland SN, Johnson JA, Savard J, Gehrman P, Perlis M, Carlson L, Campbell T. Sleeping well with cancer: A systematic review of cognitive behavioral therapy for insomnia in cancer patients. Neuropsychiatr Dis Treat 2014; 10: 1113–11124. doi: 10.2147/NDT.S47790.

Ritterband LM, Bailey ET, Thorndike FP, Lord HR, Farrell-Carnahan L, Baum LD. Initial evaluation of an internet intervention to improve the sleep of cancer survivors with insomnia. Psychooncology 2012; 21(7): 695–705. doi: 10.1002/pon.1969.

Hanly N, Mireskandari S, Juraskova I. The struggle towards ‘the new normal’: A qualitative insight into psychosexual adjustment to prostate cancer. BMC Urol 2014; 14: 56. doi: 10.1186/1471-2490-14-56.

Sharp L, Timmons A. Pre-diagnosis employment status and financial circumstances predict cancer-related financial stress and strain among breast and prostate cancer survivors. Support Care Cancer 2016; 24(2): 699–709. doi: 10.1007/s00520-015-2832-4.

Marshall-McKenna R, Morrison A, Stirling L, Hutchison C, Rice AM, Hewitt C, Paul L, Rodger M, Macpherson IR, McCartney E. A randomised trial of the cool pad pillow topper versus standard care for sleep disturbance and hot flushes in women on endocrine therapy for breast cancer. Support Care Cancer 2015; 24(4): 1821–1829. doi: 10.1007/s00520-015-2967-3.



  • There are currently no refbacks.

Copyright (c) 2018 Frances Josephine Drummond

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.